KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $18.0 million.

  • Rigel Pharmaceuticals' Shares Outstanding (Weighted Average) rose 248.86% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year increase of 248.86%. This contributed to the annual value of $17.6 million for FY2024, which is 102.29% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $18.0 million for Q3 2025, which was up 248.86% from $17.9 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $173.6 million in Q1 2023 and a low of $17.0 million during Q4 2022
  • Over the past 5 years, Rigel Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $17.9 million (recorded in 2025), while the average stood at $82.4 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Shares Outstanding (Weighted Average) tumbled by 9000.01% in 2022, and later soared by 248.86% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $170.5 million in 2021, then tumbled by 90.0% to $17.0 million in 2022, then increased by 2.06% to $17.4 million in 2023, then rose by 1.02% to $17.6 million in 2024, then grew by 2.61% to $18.0 million in 2025.
  • Its last three reported values are $18.0 million in Q3 2025, $17.9 million for Q2 2025, and $17.8 million during Q1 2025.